Biomarin's transition to rare disease specialist
The bull case argued for Biomarin: the company is transitioning from a one-blockbuster drug maker to a diversified rare disease specialist, which could attract more investor interest and drive earnings growth.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.